| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 1.106 | - | 609 | 269 | 402 | 318 | 158 | 0 | 0 | 0 |
| Total Income - EUR | 1.106 | - | 609 | 269 | 402 | 318 | 158 | 0 | 0 | 0 |
| Total Expenses - EUR | 662 | - | 537 | 492 | 500 | 637 | 568 | 481 | 608 | 477 |
| Gross Profit/Loss - EUR | 444 | - | 72 | -223 | -98 | -319 | -410 | -481 | -608 | -477 |
| Net Profit/Loss - EUR | 411 | - | 53 | -231 | -110 | -329 | -415 | -481 | -608 | -477 |
| Employees | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Italrom Pharma Consulting S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 2.095 | - | 2.825 | 2.862 | 2.720 | 2.461 | 2.099 | 1.649 | 1.188 | 764 |
| Inventories | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 34 | - | 12 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 2.061 | - | 2.813 | 2.861 | 2.720 | 2.461 | 2.099 | 1.649 | 1.188 | 764 |
| Shareholders Funds | 1.658 | - | 1.499 | 1.240 | 1.106 | 756 | 325 | -155 | -763 | -1.235 |
| Social Capital | 45 | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 438 | - | 1.326 | 1.622 | 1.615 | 1.704 | 1.774 | 1.804 | 1.950 | 1.999 |
| Income in Advance | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6420 - 6420" | |||||||||
| CAEN Financial Year |
6420
|
|||||||||
Comments - Italrom Pharma Consulting S.r.l.